poisar

Stock

ACADIA Pharmaceuticals Inc. ACAD

$27.85-3.70%

Overview

ACAD market data

Price History

ACAD price chart · 1M
O
28.93
H
28.96
L
27.63
C
27.85
Vol
180,312.00
Source
US equities market feed
Observed
Sep 3, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$28.93
Previous Close
$28.92
Day High
$28.96
Day Low
$27.63
52 Week High
$30.94
52 Week Low
$20.31
7 Day Return
-6.31%
30 Day Return
+2.47%
90 Day Return
+29.17%
1 Year Return
+23.39%
Daily Notional Volume
$5M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
12.85
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$2.30
Diluted earnings per share over the trailing twelve months.
Beta
0.86
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
33.4%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$19.69 – $30.96
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $4.9B · P/B 3.68 · P/S 4.29.

Company News

10 captured
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38Benzinga · Aug 25, 2026, 5:05 PM
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28Benzinga · Aug 25, 2026, 3:28 PM
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40Benzinga · Aug 25, 2026, 3:28 PM
European Commission Approves Acadia’s DAYBU For Rett Syndrome Patients Aged Five And Older Following Successful Phase 3 LAVENDER StudyBenzinga · Aug 24, 2026, 1:28 PM
UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49Benzinga · Aug 17, 2026, 2:28 PM
Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41Benzinga · Aug 12, 2026, 10:05 AM
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39Benzinga · Aug 10, 2026, 3:11 PM
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25Benzinga · Aug 5, 2026, 5:14 PM
ACADIA Pharmaceuticals shares are trading higher after Citizens and RBC Capital raised their respective price targets on the stock.Benzinga · Aug 5, 2026, 4:49 PM
RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $37Benzinga · Aug 5, 2026, 3:21 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock